News

Wednesday December 7, 2022

XF-73 Nasal final Phase 3 development plans

Destiny Pharma plc (“Destiny Pharma” or “the Company”) US FDA/CDC workshop highlights the need for new approaches for the prevention of hospital-acquired infections  ·    Particular support for decolonisation of pathogens […]

Thursday September 22, 2022

Notice of R&D Update Meeting

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of R&D Update Meeting Brighton, United Kingdom – 22 September 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on […]

Friday September 9, 2022

Exercise of Options and Total Voting Rights

Exercise of Options and Total Voting Rights Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, […]

Thursday September 8, 2022

Interim results for six months ended 30 June 2022

Destiny Pharma today announced its interim results for the 6 months ended 30 June 2022, which can be found here.

Wednesday September 7, 2022

Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Inves...

Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines […]

Wednesday September 7, 2022

Positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans

Destiny Pharma announces positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans  EMA endorses Destiny Pharma’s proposed single pivotal Phase 3 study design for the development […]

Friday August 26, 2022

Notice of Interim Results and Investor Presentation

Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life‐threatening infections, will announce its interim results for the period ended […]

Thursday July 28, 2022

Chair’s Investor Update

Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, today announces an Investor Update from its Chair, Nick […]

Tuesday July 26, 2022

Publication of new data on NTCD-M3

Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, today announces publication of new data on NTCD-M3, its […]

Friday March 25, 2022

Destiny’s microbiome project article published in Vantage

Destiny Pharma’s CEO, Neil Clark, discusses the Company’s microbiome project with Vantage. Read the full article here